Carregant...
3. How comprehensive can we be in the economic assessment of vaccines?
In two previous papers we argued on current vaccines economic assessment not fully comprehensive when using the incremental cost-utility analysis normally applied for treatments. Many differences exist between vaccines and drug treatments making vaccines economic evaluation more cumbersome. Four cha...
Guardat en:
| Publicat a: | J Mark Access Health Policy |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Routledge
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5956290/ https://ncbi.nlm.nih.gov/pubmed/29785253 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/20016689.2017.1336044 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|